title: What Can Molecular Diagnostics Add to Locoregional Treatment Recommendations for DCIS?
authors.affiliation: Duke University Medical Center, Department of Surgery, Division of Surgical Oncology, Durham, NC, USA.
authors.forename: E
authors.initials: E
authors.lastname: Shelley Hwang
authors.affiliation: Department of Breast Surgery, MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Alastair
authors.initials: A
authors.lastname: Thompson
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D001943:Breast Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D015994:Incidence; D015412:Mastectomy, Segmental; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000453:epidemiology / Q000235:genetics; D011379:Prognosis; D020266:Radiotherapy, Conformal; D059467:Transcriptome
chemical_list: D014408:Biomarkers, Tumor